{"url_path":"/sec/sln/8-k/2026-06-23/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-23","source_url":"https://www.sec.gov/Archives/edgar/data/1479615/0001193125-26-279577-index.html","accession_number":"0001193125-26-279577","cik":"0001479615","ticker":"SLN","issuer_name":"Silence Therapeutics plc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1479615/0001193125-26-279577-index.html","primary_entity_key":"0001479615","primary_entity_name":"Silence Therapeutics plc"},"word_count":93,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits.\n\n(d)\nExhibits.\n\n \n\nExhibit\n\nNumber\n\nDescription\n\n99.1\n\n \n\n[Silence Therapeutics plc corporate presentation dated June 23, 2026](sln-ex99_1.htm)\n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nSilence Therapeutics plc\n\nDate: June 23, 2026\n\nBy:\n\n /s/ Iain Ross\n\nName: Iain Ross\n\nTitle: Interim Principal Executive Officer and Chairman of the Board of Directors\n\n(Principal Executive Officer)"}